Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo *
暂无分享,去创建一个
[1] M. Garber,et al. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. , 1998, Genes & development.
[2] E. Sausville,et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.
[3] E. Sausville,et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. , 1999, Cancer research.
[4] B. Cullen,et al. Highly Divergent Lentiviral Tat Proteins Activate Viral Gene Expression by a Common Mechanism , 1999, Molecular and Cellular Biology.
[5] D. Hazuda,et al. Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[6] A. Giordano,et al. CDK9 (PITALRE): A multifunctional cdc2‐related kinase , 1998, Journal of cellular physiology.
[7] S H Kim,et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[8] P. Sharp,et al. HIV‐1 Tat protein promotes formation of more‐processive elongation complexes. , 1991, The EMBO journal.
[9] M. Mathews,et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.
[10] T. Rana,et al. DSIF and NELF Interact with RNA Polymerase II Elongation Complex and HIV-1 Tat Stimulates P-TEFb-mediated Phosphorylation of RNA Polymerase II and DSIF during Transcription Elongation* , 2001, The Journal of Biological Chemistry.
[11] L. Kèlland,et al. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status , 2000, Expert opinion on investigational drugs.
[12] R. Roeder,et al. Ribosomal RNA synthesis in isolated nuclei. , 1972, Journal of molecular biology.
[13] J. Chu,et al. Effects of transcription and translation inhibitors on a human gastric carcinoma cell line. Potential role of Bcl-X(S) in apoptosis triggered by these inhibitors. , 1997, Biochemical pharmacology.
[14] W. Humphreys,et al. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. , 2000, Journal of medicinal chemistry.
[15] J. Milton,et al. Identification of multiple cyclin subunits of human P-TEFb. , 1998, Genes & development.
[16] P. Sharp,et al. Positive Transcription Elongation Factor b Phosphorylates hSPT5 and RNA Polymerase II Carboxyl-terminal Domain Independently of Cyclin-dependent Kinase-activating Kinase* , 2001, The Journal of Biological Chemistry.
[17] P. Worland,et al. Structure-activity relationship studies of flavopiridol analogues. , 2000, Bioorganic & medicinal chemistry letters.
[18] S. Steinberg,et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S H Kim,et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.
[20] E. Sausville,et al. Preclinical and clinical development of cyclin-dependent kinase modulators. , 2000, Journal of the National Cancer Institute.
[21] Junmin Peng,et al. Cyclin K Functions as a CDK9 Regulatory Subunit and Participates in RNA Polymerase II Transcription* , 1999, The Journal of Biological Chemistry.
[22] E. Sausville,et al. Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication* , 2000, The Journal of Biological Chemistry.
[23] D. Hazuda,et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. , 1997, Genes & development.
[24] L. Toledo,et al. The structure-based design of ATP-site directed protein kinase inhibitors. , 1999, Current medicinal chemistry.
[25] Ping Wei,et al. A Novel CDK9-Associated C-Type Cyclin Interacts Directly with HIV-1 Tat and Mediates Its High-Affinity, Loop-Specific Binding to TAR RNA , 1998, Cell.
[26] E. Sausville,et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.
[27] B. Peterlin,et al. The Ability of Positive Transcription Elongation Factor b To Transactivate Human Immunodeficiency Virus Transcription Depends on a Functional Kinase Domain, Cyclin T1, and Tat , 1998, Journal of Virology.
[28] D. Price. P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II , 2000, Molecular and Cellular Biology.
[29] B. Peterlin,et al. Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. , 1999, Virology.
[30] L. Meijer,et al. ATP-site directed inhibitors of cyclin-dependent kinases. , 1999, Current medicinal chemistry.
[31] A. Rice,et al. PITALRE, the Catalytic Subunit of TAK, Is Required for Human Immunodeficiency Virus Tat Transactivation In Vivo , 1998, Journal of Virology.